IN2012CH01573A - - Google Patents
Download PDFInfo
- Publication number
- IN2012CH01573A IN2012CH01573A IN1573CH2012A IN2012CH01573A IN 2012CH01573 A IN2012CH01573 A IN 2012CH01573A IN 1573CH2012 A IN1573CH2012 A IN 1573CH2012A IN 2012CH01573 A IN2012CH01573 A IN 2012CH01573A
- Authority
- IN
- India
- Prior art keywords
- compounds
- bruton
- btk
- formula
- tyrosine kinase
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010028417 myasthenia gravis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2013/000259 WO2013157022A1 (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| CN201380019452.8A CN104662018B (zh) | 2012-04-20 | 2013-04-18 | 取代的杂双环化合物、组合物及其医疗应用 |
| IN1573CH2012 IN2012CH01573A (OSRAM) | 2012-04-20 | 2013-04-18 | |
| AU2013250726A AU2013250726B2 (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| CA2869954A CA2869954C (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity |
| JP2015506355A JP6182593B2 (ja) | 2012-04-20 | 2013-04-18 | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
| EP13737672.9A EP2838898B1 (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| US14/509,793 US9233983B2 (en) | 2012-04-20 | 2014-10-08 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| ZA2014/07341A ZA201407341B (en) | 2012-04-20 | 2014-10-09 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| IL235146A IL235146A (en) | 2012-04-20 | 2014-10-19 | Converted heterocyclic compounds, preparations and their medical applications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1573CH2012 IN2012CH01573A (OSRAM) | 2012-04-20 | 2013-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012CH01573A true IN2012CH01573A (OSRAM) | 2015-07-10 |
Family
ID=48794150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1573CH2012 IN2012CH01573A (OSRAM) | 2012-04-20 | 2013-04-18 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9233983B2 (OSRAM) |
| EP (1) | EP2838898B1 (OSRAM) |
| JP (1) | JP6182593B2 (OSRAM) |
| CN (1) | CN104662018B (OSRAM) |
| AU (1) | AU2013250726B2 (OSRAM) |
| CA (1) | CA2869954C (OSRAM) |
| IL (1) | IL235146A (OSRAM) |
| IN (1) | IN2012CH01573A (OSRAM) |
| WO (1) | WO2013157022A1 (OSRAM) |
| ZA (1) | ZA201407341B (OSRAM) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| AU2012318896B2 (en) | 2011-10-03 | 2017-03-02 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
| US9567326B2 (en) | 2012-05-22 | 2017-02-14 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
| SG11201500499TA (en) | 2012-08-10 | 2015-03-30 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
| CA2905935A1 (en) * | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
| CN104211703B (zh) * | 2013-05-30 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类作为布鲁顿激酶抑制剂的稠杂环化合物 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| US20150291606A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrrolopyrimidine compounds |
| CN105294571B (zh) | 2014-07-03 | 2019-04-23 | 浙江九洲药业股份有限公司 | 一种依鲁替尼中间体及其制备方法和用途 |
| SG10202006053UA (en) | 2014-08-04 | 2020-07-29 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| BR112017006305B1 (pt) * | 2014-10-06 | 2024-02-20 | Merck Patent Gmbh | Compostos heteroarila, seus usos, e composição farmacêutica |
| US10272070B2 (en) | 2014-10-14 | 2019-04-30 | The Board of Trustees of the Leland Stanford Junio r University | Method for treating neurodegenerative diseases |
| CA2965517C (en) * | 2014-10-24 | 2023-05-02 | Bristol-Myers Squibb Company | Indole carboxamides compounds useful as kinase inhibitors |
| EP3042903B1 (en) * | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| CA3014432C (en) | 2015-06-18 | 2024-05-07 | Cephalon, Inc. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| EA201890086A1 (ru) | 2015-06-18 | 2018-06-29 | Сефалон, Инк. | 1,4-замещенные производные пиперидина |
| GB201517216D0 (en) * | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) * | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| HUE051771T2 (hu) | 2015-12-15 | 2021-03-29 | Univ Leland Stanford Junior | Módszer a korral összefüggõ kognitív zavar és ideggyulladás megelõzésére és/vagy kezelésére |
| JP6916185B2 (ja) * | 2016-01-13 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋ阻害剤としてのイソキノロン類 |
| US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
| FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| EP3500569B1 (en) * | 2016-08-16 | 2022-05-18 | Merck Patent GmbH | 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof |
| MX389307B (es) | 2016-11-25 | 2025-03-20 | Carna Biosciences Inc | Derivados de oxoisoquinolina novedosos |
| CN106883235B (zh) * | 2016-12-29 | 2019-04-30 | 天津国际生物医药联合研究院 | 恶二唑类化合物的制备和应用 |
| CN110072865B (zh) * | 2017-02-08 | 2022-02-11 | 中国医药研究开发中心有限公司 | 吡咯并芳杂环类化合物及其制备方法和医药用途 |
| CN108794480A (zh) * | 2017-04-28 | 2018-11-13 | 天津药物研究院有限公司 | 吡咯并嘧啶类化合物、其制备方法和用途 |
| EP3697786B1 (en) | 2017-10-18 | 2022-08-31 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
| HRP20221207T1 (hr) * | 2017-12-13 | 2022-12-09 | Lupin Limited | Supstituirani biciklički heterociklički spojevi kao inhibitori prmt5 |
| CN109293638B (zh) * | 2018-03-27 | 2020-08-14 | 大连理工大学 | 一种增强型的靶向识别受体酪氨酸激酶的荧光传感器及细胞膜荧光成像的应用 |
| CN108707154A (zh) * | 2018-07-10 | 2018-10-26 | 刘凤娟 | 一种治疗癌症的药物溶剂合物及其制备方法 |
| KR20210068399A (ko) * | 2018-08-06 | 2021-06-09 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 | 신경퇴행성 질병의 치료를 위한 피피에이알지씨1알파 활성제로서 2-아릴벤즈이미다졸 |
| EP3847170B1 (en) * | 2018-09-06 | 2022-06-22 | F. Hoffmann-La Roche AG | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| CN109336863A (zh) * | 2018-10-04 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型酞嗪酮类btk抑制剂、制备及其应用 |
| CN109293635A (zh) * | 2018-10-04 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的p晶型及其制备方法 |
| CN109180643A (zh) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类化合物晶型a及其制备方法 |
| CN109180642A (zh) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类btk抑制剂及其应用 |
| CN109485636A (zh) * | 2018-10-04 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的盐酸盐及其制备方法与用途 |
| CN109369619A (zh) * | 2018-10-04 | 2019-02-22 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类化合物晶型b及其制备方法 |
| CN109180644A (zh) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的甲磺酸盐及其制备方法与用途 |
| CN109336864A (zh) * | 2018-10-04 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类化合物晶型n及其制备方法 |
| EP3980417B1 (en) * | 2019-06-10 | 2023-09-27 | Lupin Limited | Prmt5 inhibitors |
| CN110305140B (zh) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| CN114728170B (zh) | 2019-12-20 | 2024-03-01 | 纽韦卢森公司 | 对核受体具有活性的化合物 |
| WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| WO2021124277A1 (en) | 2019-12-20 | 2021-06-24 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JP7713954B2 (ja) | 2020-03-31 | 2025-07-28 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
| CA3174252A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| JP7805983B2 (ja) * | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| CN116854709A (zh) * | 2022-03-28 | 2023-10-10 | 药雅科技(上海)有限公司 | Bruton′s酪氨酸激酶可逆抑制剂及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| CA2450777C (en) * | 2001-08-10 | 2013-04-09 | Novartis Ag | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| ATE387197T1 (de) | 2001-11-13 | 2008-03-15 | Merck Frosst Canada Ltd | Cyanoalkylamino-derivate als protease-hemmer |
| US20060183746A1 (en) * | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| CN101124227A (zh) * | 2004-11-10 | 2008-02-13 | Cgi制药有限公司 | 可用作激酶活性调节剂的咪唑并[1,2-a]吡嗪-8-基胺 |
| WO2007002313A2 (en) | 2005-06-24 | 2007-01-04 | Bristol-Myers Squibb Company | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants |
| WO2007021937A2 (en) * | 2005-08-11 | 2007-02-22 | Ariad Pharmaceuticals, Inc. | Unsaturated heterocyclic derivatives |
| CA2620352A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| JP2009531274A (ja) | 2005-12-07 | 2009-09-03 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | キナーゼ阻害性ピロロピリジン化合物 |
| EP2114941B1 (en) | 2006-12-22 | 2015-03-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| HRP20130615T1 (en) | 2008-02-05 | 2013-08-31 | F. Hoffmann - La Roche Ag | Novel pyridinones and pyridazinones |
| WO2009114180A1 (en) | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| CN104059066A (zh) | 2008-06-11 | 2014-09-24 | 健泰科生物技术公司 | 二氮杂咔唑和使用方法 |
| WO2010000633A1 (en) | 2008-07-02 | 2010-01-07 | F. Hoffmann-La Roche Ag | Novel phenylpyrazinones as kinase inhibitors |
| JP2011526931A (ja) | 2008-07-03 | 2011-10-20 | エグゼリクシス， インコーポレイテッド | Ｃｄｋモジュレーター |
| CA2730116A1 (en) | 2008-07-08 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors |
| UY31984A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
| ES2461494T3 (es) | 2008-07-18 | 2014-05-20 | F. Hoffmann-La Roche Ag | Nuevas fenilimidazopirazinas |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| WO2010068806A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
| WO2010068788A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
| WO2010068810A2 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| SG171815A1 (en) | 2008-12-19 | 2011-07-28 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CN102292329B (zh) | 2009-04-24 | 2014-09-03 | 霍夫曼-拉罗奇有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
| ES2444777T3 (es) | 2009-06-12 | 2014-02-26 | Bristol-Myers Squibb Company | Compuestos de nicotinamida útiles como moduladores de quinasas |
| EP2789615B1 (en) | 2009-08-11 | 2017-05-03 | Bristol-Myers Squibb Company | Azaindazoles as Btk kinase modulators and use thereof |
| DK2473049T3 (en) * | 2009-09-04 | 2019-04-01 | Biogen Ma Inc | INHIBITORS OF BRUTON'S TYROSINKINASE |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| NZ600637A (en) | 2010-01-27 | 2014-07-25 | Boehringer Ingelhelheim Internat Gmbh | Pyrazole compounds as crth2 antagonists |
| EP2694218B1 (en) * | 2011-04-05 | 2019-05-22 | ETH Zurich | Droplet dispensing device and light source comprising such a droplet dispensing device |
| CN103732596B (zh) * | 2011-07-08 | 2016-06-01 | 诺华股份有限公司 | 吡咯并嘧啶衍生物 |
| TW201311669A (zh) | 2011-08-17 | 2013-03-16 | Hoffmann La Roche | 布魯頓氏酪胺酸激酶（ｂｒｕｔｏｎ’ｓ ｔｙｒｏｓｉｎｅ ｋｉｎａｓｅ）之抑制劑 |
-
2013
- 2013-04-18 IN IN1573CH2012 patent/IN2012CH01573A/en unknown
- 2013-04-18 AU AU2013250726A patent/AU2013250726B2/en not_active Ceased
- 2013-04-18 JP JP2015506355A patent/JP6182593B2/ja active Active
- 2013-04-18 CA CA2869954A patent/CA2869954C/en active Active
- 2013-04-18 WO PCT/IN2013/000259 patent/WO2013157022A1/en not_active Ceased
- 2013-04-18 CN CN201380019452.8A patent/CN104662018B/zh not_active Expired - Fee Related
- 2013-04-18 EP EP13737672.9A patent/EP2838898B1/en active Active
-
2014
- 2014-10-08 US US14/509,793 patent/US9233983B2/en active Active
- 2014-10-09 ZA ZA2014/07341A patent/ZA201407341B/en unknown
- 2014-10-19 IL IL235146A patent/IL235146A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL235146A (en) | 2017-07-31 |
| CA2869954A1 (en) | 2013-10-24 |
| WO2013157022A1 (en) | 2013-10-24 |
| EP2838898A1 (en) | 2015-02-25 |
| JP2015514749A (ja) | 2015-05-21 |
| CN104662018B (zh) | 2017-10-24 |
| ZA201407341B (en) | 2015-06-24 |
| US9233983B2 (en) | 2016-01-12 |
| CN104662018A (zh) | 2015-05-27 |
| AU2013250726B2 (en) | 2017-01-05 |
| CA2869954C (en) | 2023-01-03 |
| EP2838898B1 (en) | 2017-01-18 |
| JP6182593B2 (ja) | 2017-08-16 |
| US20150064196A1 (en) | 2015-03-05 |
| AU2013250726A1 (en) | 2014-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012CH01573A (OSRAM) | ||
| MX2013012983A (es) | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. | |
| EA201492250A1 (ru) | Гетероциклическое соединение | |
| IN2015DN02008A (OSRAM) | ||
| BR112017014770A2 (pt) | compostos bicíclicos, composições e aplicações médicas dos mesmos | |
| PH12013502445A1 (en) | Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| PH12015500488A1 (en) | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| PH12018500533A1 (en) | Pyrazolyl-substituted heteroaryls and their use as medicaments | |
| MY155639A (en) | 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors | |
| MX2015001715A (es) | Compuestos de pirrolopirimidina novedosos como inhibidores de proteinas quinasas. | |
| PH12015502563A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| SG194728A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX2014014828A (es) | Compuestos de 5-azaindazol y metodos de uso. | |
| MX349372B (es) | Inhibidores de la tirosina-cinasa de bruton. | |
| MX2014005285A (es) | Compuestos biciclicos de piperazina. | |
| MX392440B (es) | Inhibidores de tirosina quinasa de bazo (syk). | |
| MY143483A (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | |
| EA201592033A1 (ru) | 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА | |
| NZ601267A (en) | Fused heteroaromatic pyrrolidinones as syk inhibitors | |
| IN2014CN03265A (OSRAM) | ||
| MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
| EP2635587A1 (en) | Novel 6-arylamino pyridone carboxamide as mek inhibitors | |
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| IN2014DN07885A (OSRAM) |